Thus, the inhibition of RANKL expression by denosumab therapy is expected to induce abnormal proliferation and differentiation of osteoblasts and bring about semaphorin 3A-mediated osteosarcoma carcinogenesis. This evidence concerns the gene SEMA3A and osteosarcoma.